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Abstract
The extraocular muscles differ from other skeletal muscles in many respects but 
most strikingly in their response to neuromuscular diseases expected to affect the 
whole body. Oculomotor disturbances are not typical features of ALS. Recent data 
ascribe the muscle tissue an important role in the pathophysiology of ALS, with 
early involvement of the neuromuscular junctions and loss of axonal contact. We 
show that the extraocular muscles of terminal ALS donors and also of mice models 
of ALS maintain their morphology and well-preserved neuromuscular junctions 
until the end stages of the disease, whereas the limb muscles are severely affected 
and their neuromuscular junctions start losing contact with the supplying axons 
early in the course of ALS. There are intrinsic differences between the extraocular 
and limb muscles with respect to neurotrophic factors and Wnt isoforms and fun-
damental differences in their response to ALS that cannot be explained by the aging 
process. We propose that these differences may be instrumental in the selective 
sparing of the extraocular muscles in ALS.
Keywords: extraocular muscle, ALS, pathophysiology, neurotrophic factor, 
neuromuscular junction, Wnt, BDNF, GDNF, NT-3, NT-4, S-100B, synaptophysin, 
p75, neurofilament, Wnt1, Wnt3a, Wnt5a, Wnt7
1. Introduction
Amyotrophic lateral sclerosis (ALS) is a late-onset progressive neurodegenera-
tive disorder affecting both the upper and lower motor neurons. It is characterized 
by increasing muscle weakness, paresis, and paralysis, and although the course of 
the disease may vary considerably, death usually occurs within 3–5 years due to 
respiratory failure. While almost all skeletal muscles, including the cranially inner-
vated muscles responsible for speech and swallowing, are affected in ALS, oculo-
motor disturbances are not dominant or typical features of this disease, not even 
in patients with long-duration ALS, and eye movements may remain the only form 
of communication available to these patients at the end stages of the disease. The 
cranial nerve nuclei supplying the eye muscles appear rather normal in terminal 
ALS patients [1], and abnormalities in eye motility in ALS patients, when present, 
have been ascribed to supranuclear deficits [2].
The pathophysiology of the neurodegenerative process in ALS has been pro-
posed to be due to a number of different causes. The traditional point of view has 
been that ALS is a motor neuron disease that progresses to the periphery where it 
affects the muscles, due to the typical loss of motor neurons in the anterior horns of 
the spinal cord and sclerosis of the lateral corticospinal tracts. However, a number 
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of studies suggest an inverse course of events, with changes starting at the periph-
ery and progressing along the motor neurons toward the CNS, reviewed by [3–5]. In 
SOD1G93A transgenic mice, it has been shown that peripheral denervation occurs 
in the limb muscles before the animals become clinically weak or motor neuron 
loss is detected [6]. Similar results were also reported for a patient with ALS who 
died unexpectedly, leading the authors to propose that motor neuron pathology in 
ALS begins at the distal axon end and proceeds in a “dying back” pattern [6]. Later, 
it has been shown that muscle-restricted expression of three different SOD1 gene 
variants can initiate the non-autonomous degeneration of motor neurons typical 
of ALS [7], truly showing that the muscle itself may be a major player in the early 
stages of ALS.
A unifying model compiling extensive experimental data from SOD1 transgenic 
models of ALS [3] proposes that although motor neuron degeneration and death are 
the primary causes of the progressive paralysis, neighboring nonneuronal cells are 
also involved in the toxicity and damage development. In this model, the earli-
est event is the retraction of motor axons from their muscle synapses, before any 
symptoms of the disease are present.
The extraocular muscles (EOMs) are unique in many respects and are con-
sidered a separate muscle class, allotype. They are both the fastest and the most 
fatigue-resistant muscles in the body, and their fiber-type composition is very 
complex [8, 9]. The unique properties of the EOMs are reflected in their expression 
profile that differs from that of limb muscle in over 300 genes [10]. However, the 
most striking property of EOMs is their varied behavior in disease. The EOMs are 
known to be selectively involved in certain diseases like mitochondrial myopathies, 
myasthenia gravis, and Miller Fisher syndrome, but preferentially spared in other 
devastating diseases like Duchenne muscular dystrophy and merosin-deficient 
muscular dystrophy, that affect all other muscles in the body [11–13].
The extraocular muscles are richly innervated, and their motor units are very 
small, with 7–25 muscle fibers, in contrast to the motor units of limb muscles, 
which typically contain hundreds of muscle fibers. The majority of the nerve fibers 
in the EOMs are large and myelinated and innervate a typical single “en plaque” 
endplate in the middle portion of each muscle fiber. The remaining 15–20% of the 
EOM nerve fibers are small and innervate many small, “en grappe” motor endplates 
along the length of a muscle fiber (the so-called multiply innervated muscle fibers, 
reviewed in [11]). This traditional description of the innervation of the EOMs has 
been significantly changed by the recent report of a subpopulation of muscle fibers 
that exhibit multiple large “en plaque” nerve endings [14]. The NMJs of the EOMs 
also differ from limb muscle in retaining expression of the fetal gamma subunit of 
the acetylcholine receptor (AChR), in addition to the adult epsilon subunit, typi-
cally present in mature motor endplates [14, 15]. We have shown that the NMJs 
of the human EOMs have a different immunoreactivity pattern than that seen 
in limb muscles for antibodies against gangliosides GQ1b, GT1a, and GD1b [16]. 
Gangliosides are a large family of sialylated glycosphingolipids highly enriched in 
neuronal and glial plasma membranes and important for the development, func-
tion, and maintenance of the nervous system. Complex gangliosides have neuro-
trophic factor-like activity and may regulate the expression levels of neurotrophic 
factors and their receptors [17]. Notably, there have been at least two case reports of 
ALS associated with antibodies against gangliosides [18, 19].
Given that the EOMs differ significantly from the limb and trunk muscles 
with respect to their response to disease and given the more recent view that the 
muscle itself may play a key role in the pathophysiology of ALS, we first inves-
tigated whether there are any major differences between the EOMs and the limb 
muscles of terminal ALS donors [20]. Thereafter, we investigated neuromuscular 
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junction integrity [21–23], neurotrophic factors (BDNF, NT-3, NT-4, GDNF) 
and their receptors (p75NTR, TrkB, TrkC) [24, 25], and relevant Wnt isoforms 
(Wnt1, Wnt3a, Wnt5a, Wnt7a) [26], as possible important puzzle pieces to better 
understand the pathophysiology of ALS and the selective sparing of the EOMs in 
the disease.
2.  The extraocular muscles of terminal ALS donors are remarkably well 
preserved
We compared the general morphology, fiber-type content, fiber area and 
myosin heavy chain (MyHC) composition of EOM, biceps brachii, vastus lateralis, 
and tibialis anterior muscle samples collected from eight terminal ALS donors 
(age 58–80 years) and from three age-matched (age 72–86 years) and a younger 
(age 26 years) control, with ethical approval, using immunohistochemistry and 
SDS-PAGE [20]. There were five cases of sporadic ALS and three cases of familial 
ALS. The MyHC isoforms are the major determinants of key contractile and 
biochemical characteristics of the myofibers including shortening velocity and 
power and therefore very good markers of the physiological properties of myofi-
bers. Our study showed that the morphology of the ALS limb muscle samples is 
clearly pathological. All limb muscle samples from terminal ALS donors exhibit 
typical signs of myofiber type grouping, myofiber splitting, necrosis, increased 
connective tissue, fatty replacement, and ongoing regeneration, with a very wide 
range of myofiber areas. In contrast, the EOM samples from the same donors 
show remarkably well-preserved morphology. In 18 out of the 43 EOM samples 
examined, larger variation in fiber area was apparent than in the control samples 
and irrespectively of being sporadic or familial ALS cases. In fact, areas that 
appear well preserved reveal a general atrophy of all myofiber types, whereas areas 
that appear more affected generally show atrophy of the myofibers containing 
MyHCslow and hypertrophy of the myofibers containing MyHCfast2A. In 20 EOM 
samples, increased connective tissue amounts were noted, either around individual 
myofibers or around groups of myofibers. The changes noticed vary among donors 
and among different EOM samples from a given donor. Centrally placed nuclei are 
rarely detected. The MyHC content, determined with SDS-PAGE of whole EOM 
extracts, varies among ALS donors, whereas it is rather similar among control 
EOM samples [20]. This variation in MyHC content at the whole muscle level can 
be interpreted as reflecting different levels of involvement, and, to a lesser degree, 
naturally occurring variation among subjects [8].
Given that this first study clearly shows that the human EOMs are remarkably 
well preserved at the end stage of ALS [20] and because the EOMs are known 
to show a divergent behavior in disease, we decided to further investigate these 
muscles in ALS, comparing the EOMs and limb muscle samples from human donors 
and from mouse models of ALS, taking a “muscle perspective” to study the patho-
physiology of the disease.
3.  Maintained neuromuscular junction occupancy in the extraocular 
muscles at end stages of ALS
In the SOD1G93A mouse, the most widely used mouse model of ALS, it has been 
shown that loss of contact between the axons and the myofibers, at the neuro-
muscular junctions, occurs early in the course of the disease and indeed precedes 
detection of loss of motor neurons in the spinal cord [6]. Similar findings have been 
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reported in ALS patients who died of other reasons early in the course of ALS [6]. 
Furthermore, data show that muscle-specific alterations are sufficient to trigger 
neuromuscular pathology and distal degeneration of motor neurons [5, 7], suggest-
ing that the muscle itself may play an important role in the pathophysiology of ALS.
We investigated [21] whether there are signs of loss of contact between the 
axons and the myofibers, at the neuromuscular junctions of the EOMs, extensor 
digitorum longus, tibialis anterior, and gastrocnemius and soleus muscles from 
seven SOD1G93A transgenic and six control mice. We used triple labeling immuno-
histochemistry with antibodies against neurofilament protein and synaptophysin 
to identify the axonal side of the neuromuscular junctions and their axons and 
alpha-bungarotoxin, to identify the muscle side of the neuromuscular junctions, 
in the same muscle section. Our study confirmed that, as described above for the 
human EOMs of terminal ALS donors, the eye muscles in this animal model of ALS 
also show rather well-preserved morphological features, in clear contrast to the 
limb muscles of the same animal, at the end stage of the disease. We could confirm 
previously reported findings [6] of significant loss of contact between the nerve 
and myofiber in approximately 33% of the neuromuscular junctions in limb muscles 
of the ALS mouse model, whereas in the limb muscles of the control animals, only 
approximately 4.6% of the neuromuscular junctions lack contact with the supply-
ing nerve (p = 0.0071). In contrast, the number of neuromuscular junctions lacking 
nerve contacts in the EOMs is extremely low and similar between transgenic (1.9%) 
and control (1.7%) animals (p = 0.659) [21].
Similarly, the neuromuscular junctions of the EOMs of terminal ALS donors 
show maintenance of their integrity [22, 23]. In a study of 7 terminal ALS donors 
(age 58–80 years, three cases with SOD1D90A genotype) and 10 controls (adults 
aged 34–53 years and elderly aged 69–83 years), we compared the EOMs and 
the limb muscles with respect to the presence and distribution of neurofilament 
light subunit (marker of the axons in nerves and at the neuromuscular junction), 
synaptophysin (marker of synaptic vesicles and thereby of functioning neuromus-
cular junctions), S100B, p75NTR and glial fibrillary acidic protein (GFAP) which 
are markers of terminal Schwann cells at the neuromuscular junction, and alpha-
bungarotoxin, which labels the muscle side of the synapse [23]. GFAP and p75NTR 
are upregulated in Schwann cells after injury [27–29]. Two groups of control donors 
(adult and elderly) were included in this and all our studies of ALS in order to dis-
tinguish between the effects of normal aging and those related to ALS. This pioneer 
study showed that there is a dramatic decrease in the number of neuromuscular 
junctions and nerve axons containing neurofilament light subunit in limb muscles 
of terminal ALS donors, whereas the EOMs maintain neurofilament light subunit 
in their neuromuscular junctions and nerves. There is also a significant decrease in 
neuromuscular junctions labeled with synaptophysin in the limb muscles but not 
in the EOMs of terminal ALS donors. Together, these results confirm that there is a 
marked loss of nerve-muscle contacts in the limb muscles of terminal ALS donors, 
whereas the EOMs succeed in maintaining their neuromuscular junctions until the 
end stage of the disease. The neuromuscular junctions of limb muscles show also 
massive loss of S100B and p75NTR in ALS, whereas the staining pattern of GAFP 
is maintained. In contrast, the neuromuscular junctions in the EOMs of terminal 
ALS donors also show loss of S100B but have an unchanged pattern regarding 
the other two Schwann cell markers, GFAP and p75NTR. The loss of S100B can be 
interpreted as due to downregulation rather than a sign of loss of Schwann cells, 
given that the other two markers remain unchanged. It may also indicate a disturbed 
calcium homeostasis as an early step toward the loss of the neuromuscular junction 
in ALS. In summary, this study shows fundamental differences between the limb 
muscles and the EOMs of terminal ALS donors with a significant impact of the 
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disease on important synaptic proteins normally present in the motor axons and 
terminal Schwann cells in the limb muscles, whereas the neuromuscular junctions 
in the EOMs are only very mildly affected [23].
Another study has in addition revealed fragmentation of the postsynaptic mem-
brane, decreased density of acetylcholine receptors, and absence of nerve sprouting 
in denervated neuromuscular junctions in the limb muscles of the SOD1G93A 
mouse model of ALS, whereas no such changes are present in the neuromuscular 
junctions of the EOMs of the same animals [30].
In the context of motor axon retraction from the muscle synapse being an early 
event in the pathogenesis of ALS, it is of particular interest to further investigate 
the cellular and molecular microenvironment of the neuromuscular junctions of the 
extraocular muscles, as they may provide cues to the unique resistance of the EOMs 
to ALS.
4.  Important differences in neurotrophic factors between extraocular 
and limb muscles
Alterations in the expression of target-derived neurotrophic factors and in their 
signaling pathways have been reported in ALS. Neurotrophic factors are important 
for survival and maintenance of neurons [31–33]. Target-derived neurotrophic 
factors can be transported to lower motor neurons from other cells, including the 
muscle cells, by retrograde transport, and from upper motor neurons, by antero-
grade transport, and act as signaling molecules [31–33]. Among neurotrophic 
factors, brain-derived neurotrophic factor (BDNF) is of particular interest due to 
its capacity to promote motor neuron survival and motor axon growth [32–34]. 
Glial cell line-derived neurotrophic factor (GDNF) is also relevant as it is capable of 
rescuing motor neurons from injury-induced cell death [35], and neurothrophin-4 
(NT-4) plays a role in growth and remodulation of adult motor neurons [36, 37], 
whereas NT-3 is of particular importance for sensory neurons.
Data on the SOD1G93A mouse model of ALS show important differences 
between the EOMs and the limb muscles over time regarding the levels of expres-
sion of neurotrophic factors [24]. The authors compared the expression levels of 
BDNF, GDNF, NT-3, and NT-4, determined with quantitative RT-PCR, in limb 
(soleus and gastrocnemius) and extraocular muscles at the early stage (50 days) 
and at the end stage (150 days) of the disease. Starting with the control animals, the 
EOMs differ from the limb muscles by having significantly lower levels of BDNF 
and NT-3 mRNA at age 50 days. At 150 days, the control EOMs have significantly 
lower levels of BDNF and NT-4 mRNA than the limb muscles from the same 
animals. In the limb muscles of control animals, mRNA levels of BDNF increase 
significantly from 50 to 150 days of age, whereas the levels of NT-3 decrease dra-
matically. In the control EOMs, the mRNA levels of BDNF, GDNF, NT-3, and NT-4 
remain unchanged from 50 to 150 days of age [24].
In the transgenic animals, the expression levels of BDNF increase significantly 
from 50 to 150 days, that is, from the early stage of ALS, when the limb muscle mor-
phology is still normal, to the end stage of the disease, when the limb muscles are 
extremely affected. Compared to the controls, the limb muscles of the transgenic 
animals show significantly lower levels of NT-4 at 50 days and significantly higher 
levels of GDNF at 150 days. The transgenic EOMs show no change in the levels of 
expression of BDNF or GDNF and show significant decrease in NT-3 and increase 
in NT-4, over time between 50 and 150 days, and the morphology is comparable to 
that of the age-matched controls. Compared to the controls, the EOMs of the G93A 
animals show significantly higher levels of GDNF and NT-3 at 50 days, whereas 
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no significant differences are detectable at 150 days. Finally, comparison between 
the EOMs and limb muscles of transgenic animals shows no significant differences 
in the levels of expression of any of the four neurotrophic factors at 50 days but 
significantly higher levels of BDNF in the limb muscles at 150 days [24].
Because no significant changes in the levels of expression of BDNF detected 
with quantitative RT-PCR are apparent in either the limb or EOMs of the transgenic 
animals at any stage, the authors dismiss a possible role for this neurotrophic factors 
on ALS. The BDNF results obtained in the SOD1G93A mice are in agreement with a 
previous report from muscle samples of ALS patients [38]. In contrast, the GDNF 
mRNA levels are significantly upregulated in the EOMs of the SOD1G93A mice 
at 50 days, and the authors suggest that this early upregulation is triggered by the 
disease and seminal for the maintenance of the general morphology of the EOMs 
and in particular for their capacity of keeping intact neuromuscular junctions. They 
interpret the upregulation of GDNF in the end stage in the limb muscles as reflect-
ing the advanced motor neuron degeneration. Similarly, the upregulation of NT-3 in 
the EOMs detected at 50 days is also proposed to be triggered by ALS and to protect 
the EOMs, whereas early downregulation of NT-4 in the limb muscles is suggested 
to be detrimental and contribute to the loss of axonal contact at the neuromuscular 
junctions [24].
At the cellular level, there are also important differences in the patterns of 
distribution of neurotrophic factors between the EOMs and limb muscles, both 
among controls and among SOD1G93A animals at 50 and 150 days [25]. In the limb 
muscles of control animals, GDNF, BDNF, NT-3, and NT-4 are present in the vast 
majority of the neuromuscular junctions at 50 and 150 days, whereas that is the 
case in only a little over half of the neuromuscular junctions in the control EOMs, 
at 50 and 150 days. The proportion of neuromuscular junctions containing BDNF 
and NT-4 is significantly higher in the limb muscles than in the EOMs of control 
animals at 50 days, and the same is true for the proportion of neuromuscular junc-
tions containing BDNF and GDNF at 150 days. Particularly noteworthy is that the 
limb muscles of SOD1G93A animals show a significant decrease in the proportion of 
neuromuscular junctions containing BDNF, GDNF, and NT-4 at 150 days, whereas 
the EOMs maintain their pattern. The same is true for the presence of the receptors 
p75NTR, TrkB, and TrkC, which decline significantly in the neuromuscular junctions 
of the limb muscles of the SOD1G93A animals at 150 days, but not in their EOMs. 
TrkB is a high-affinity tyrosine kinase receptor specific for BDNF and NT-4, TrkC is 
a high-affinity tyrosine kinase receptor specific for NT-3, and p75NTR is a low-affinity 
receptor for BDNF, NT-3, and NT-4 [39]. There are only discrete differences between 
the control and the SOD1G93A animals with respect to patterns of neurotrophic 
factors in the nerve axons and the myofibers of both EOM and limb muscles [25].
Taken together, these studies [24, 25] clearly show both at the mRNA level and 
immunohistochemically that the EOMs have lower neurotrophic factor levels than 
the limb muscles, in control mice. One possible explanation resides in the differ-
ences in innervation between these muscles, as the EOMs have a rich population 
of multiply innervated myofibers, in contrast to the exclusively twitch myofibers 
of limb muscles, and the developmental fates of these different types of axons are 
dependent upon target-derived neurotrophic factors [40]. They also show that the 
significant changes in neurotrophic factors in limb muscles of transgenic animals 
are not related to normal aging.
Studies of neurotrophic factors in muscle tissue pose a technical challenge and 
clinical trials in ALS have not led to the desired effects, but the early detection 
of alterations in the levels of expression of neurotrophic factors and the distinct 
patterns observed in the EOMs versus limb muscles indicate that it is too early to 
dismiss their possible roles in the pathophysiology of ALS and in particular in the 
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selective capacity of the EOMs to maintain neuromuscular junctions and remain 
rather unaffected in the disease.
5. Differences in Wnt profiles between extraocular and limb muscles
Several Wnt proteins, including Wnt1, Wnt3a, Wnt 5a, and Wnt7a, are highly 
expressed at the neuromuscular junction, in muscle fibers, and in motor neurons, 
and abnormal Wnt signaling has been reported in ALS and a number of other 
neuromuscular conditions [41–46]. In particular, Wnt1 has been assigned impor-
tant roles in muscle regeneration and in synaptic plasticity, acting on both sides of 
the synapse [41, 47]. Wnt3a modulates the formation of neuromuscular junctions 
and promotes nerve outgrowth [48–50], whereas Wnt5a is important for motor 
neuron survival during development [51]. Wnt7a plays an important role in synaptic 
assembly and plasticity and remodeling of incoming axons [52] and has also been 
shown to have positive effects on the myofibers [53, 54]. Furthermore, Riluzole, the 
only medical treatment available for ALS, enhances Wnt/beta catenin signaling.
We have performed a comprehensive immunohistochemical study comparing 
the distribution of Wnt1, Wnt3a, Wnt5a, and Wnt7a in the EOMs and limb muscle 
samples (biceps brachii, vastus lateralis, and tibialis anterior) from six terminal 
ALS donors, younger controls (mean age 41 years for EOMs and 33 years for limb 
muscles, referred to as adult controls), and older controls (mean age 75 years for 
EOM and 76 years for limb, referred to as elderly controls), and we have reported 
significant differences and suggested a role for Wnts in the different behaviors of 
EOMs and limb muscles in ALS [26].
In the adult control EOMs, roughly 71% of the axons are Wnt1 positive, and in 
the elderly controls, merely 12% of the axons contain Wnt1, whereas in the EOMs 
of terminal ALS donors, 43% of axons are labeled for Wnt1, clearly showing that 
they preferentially maintain Wnt1 in their nerves. The limb muscles of terminal 
ALS donors contain significantly less Wnt1-positive axons than the EOMs, with 
extremely high variation among the different donors. No statistically significant 
differences between the three limb muscle groups are detectable regarding the pres-
ence of Wnt1 in the motor nerves. Wnt1 is present in almost 40% of the myofibers 
in the EOMs of adult controls and almost in all myofibers of terminal ALS donors, 
whereas it is not present in limb myofibers of adult controls or terminal ALS donors.
With regard to Wnt3a, it is present in the vast majority of axons in both the 
EOMs of adult controls and ALS terminal donors, but again it is significantly lower 
in the elderly control EOMs. In the limb muscles of all groups, the percentage of 
axons containing Wnt3a is significantly lower than in the EOMs, with approxi-
mately 75% fewer Wnt3a axons. Approximately 17% of the myofibers contain 
Wnt3a in adult control EOM, whereas almost all myofibers in the EOMs of terminal 
ALS donors are positive. Higher levels of Wnt3a are present in adult control limb 
myofibers, but in contrast Wnt3a is practically absent in the limb muscle fibers of 
terminal ALS donors.
Wnt5a is present in practically all EOM axons both in adult controls and termi-
nal ALS donors and is somewhat lower in the EOMs of elderly controls. Similarly, 
practically all limb muscle axons, irrespective of group, are Wnt5a positive. Wnt5a, 
seen as weak immunostaining, is present in almost all myofibers of control adult 
EOMs and terminal ALS donors, whereas it is not present in limb myofibers of adult 
controls or terminal ALS donors.
A very large proportion of the axons in the EOMs of adult controls and terminal 
ALS donors are Wnt7a positive, whereas a significantly lower number is found in 
the EOMs of the elderly controls. A similar proportion of Wnt7a-positive axons 
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are present in the limb muscles of both adult controls and terminal ALS donors, 
but a significantly higher number of positive axons are found in the limb muscles 
of elderly controls. Only approximately 20% of the myofibers in the adult control 
EOMs contain Wnt7a, but in the EOMs of terminal ALS donors, this number 
increases significantly almost 60%. In the limb muscles, Wnt7a is present in more 
than half of the myofibers of the adult controls and practically in all myofibers in 
the elderly controls. The differences found between adult controls and terminal ALS 
donors regarding Wnt7a in limb myofibers are not significant, probably due to large 
interindividual variation among the donors.
Data collected in controls and in the SOD1G93A mouse model of ALS [26] indi-
cates that practically all neuromuscular junctions in control EOMs and limb muscles 
express Wnt1, Wnt3a, Wnt5a, and Wnt7 at 50 and 150 days. The same is true for 
the transgenic EOMs at both 50 and 150 days and the transgenic limb muscles at 
50 days, whereas a significantly decrease in the proportion of neuromuscular junc-
tions co-expressing the different Wnt isoforms is clearly apparent in the transgenic 
limb samples at 150 days.
6. Summary
In summary, the EOMs remain remarkably well preserved until the end stages of 
ALS, both in human terminal donors and in mouse models of ALS. They maintain 
the composition of their neuromuscular junctions and do not loose contact with the 
supplying axon. Furthermore, important differences exist between the EOMs and 
the limb muscles with respect to neurotrophic factors and Wnts:
• The mRNA levels of BDNF, NT-4, and NT-3 and the detection of BDNF, NT-4, 
NT-3, and GDNF at the protein level are lower in the EOMs than in the limb 
muscles of control animals at 50 and/or 150 days.
• NT-3 is upregulated in the EOMs of SOD1G93A mice at 50 days and may be 
protective. A similar difference in GDNF may also be advantageous for the 
EOMs and protect their motor neurons.
• There is early downregulation of NT-4 in the limb muscles of SOD1G93A mice 
compared to the controls at the same age, which coincides with the timing of 
early loss of motor axon occupancy at the neuromuscular junctions of limb 
muscles in this ALS model [6].
• The proportion of neuromuscular junctions in the EOMs positive for BDNF, 
GDNF, and NT-4 is not changed between the controls and the transgenic mice 
at 150 days, whereas there is a significant decrease in the limb muscles of the 
SOD1G93A animals compared to the controls at late stage and there is also a 
significant decrease over the course of the disease in the limb muscles of the 
transgenic mice. Again, these changes in neurotrophic factors parallel the loss 
of axonal occupancy at the neuromuscular junctions of the limb muscles of 
transgenic animals and these neurotrophic factors are known to play crucial 
roles in regulating the synapses [55, 56].
• There is a significant decrease in the neurotrophic factor receptors p75NTR, 
TrkB, TrkC, and GFR-alpha1 in the neuromuscular junctions of terminal 
SOD1G93A mice, whereas they are maintained in the neuromuscular junctions 
of terminal transgenic EOMs.
9The Extraocular Muscles Are Selectively Spared in ALS
DOI: http://dx.doi.org/10.5772/intechopen.89504
• Wnt1 and Wnt3a are present in a larger proportion of axons in the human 
control EOMs than in the limb muscles. The myofibers in the control EOMs 
contain higher Wnt1 and Wnt5a and lower Wnt3a and Wnt7a than the myo-
fibers of limb muscles, and although the exact implications of these intrinsic 
differences in Wnt isoform profiles remain to be determined, they may be 
relevant for the selective sparing of the EOMs in ALS.
• Wnt1 and Wnt3a are present at significantly higher levels in the axons and 
the muscle fibers of the EOMs than in the axons or muscle fibers of the limb 
muscles of terminal ALS donors. Because Wnt1 plays a role in synaptic plastic-
ity and muscle regeneration and in neuromuscular junction formation during 
fetal development and Wnt3a has similar roles, these differences between 
EOMs and limb muscles are likely to be of importance for the selective sparing 
of the EOMs, and in particular of their neuromuscular junctions, in ALS.
Altogether, these data show important differences between the EOMs and limb 
muscles with regard to neurotrophic factors and four different Wnt isoforms, both 
at base line and in ALS, that likely play a role in the selective sparing of the EOMs in 
ALS. These data also suggest that muscle itself may provide a door for the develop-
ment of new treatment strategies in the future.
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